S_mnary Questionnaires assessing a range of quality of life (QOL) outcomes were completed by 200 adult bone marrow transplant (BMT) recipients from five BMT treatment centres. Respondents had undergone allogeneic (46%) or autologous BMT (54%) for a haematological malignancy and were disease free and at least 12 months post BMT (mean 43 months). Variability in post-BMT QOL was reported with deficits in physical, sexual and occupational functioning particularly likely. Allogeneic recipients reported poorer QOL than autologous recipients. Greater age at BMT, lower level of education and more advanced disease at BMT were consistent risk factors for poorer QOL. Contrary to previous research, evidence for improved functional status with the passage of time post BMT was obtained. Factors generally not associated with post-BMT QOL included disease diagnosis, dose of total body irradiation, presence of chronic graft-versus-host disease (GVHD), type of GVHD prophylaxis and extent of marrow graft match. In conclusion, while many BMT recipients reported normal QOL, the majority indicated that their QOL was compromised relative to premorbid status. Prospective, longitudinal research will be necessary to further identify risk factors for poor post-BMT QOL and identify the temporal trajectory of post-BMT QOL.
Bone marrow transplantation (BMT) is used as curative treatment for a variety of life-threatening, primarily malignant, diseases (Champlin and Gale, 1984; Blume, 1989, 1990) . While initially used as a treatment of 'last resort', advances in transplant immunology and immunogenetics, human leucocyte antigen (HLA) testing, pre-BMT conditioning and supportive care have resulted in improved clinical outcomes as well as expansion of the range of diseases and patients for which BMT is indicated. As a result, BMT has undergone a dramatic increase in utilisation (Bortin and Rimm, 1989) .
While physical 'late effects' of BMT have been recognised, including pulmonary problems, cataracts, sterility, chronic graft-versus-host disease (GVHD) and development of a secondary malignancy (Deeg, 1990; Kolb and Bender-Gotze, 1990) , less is known about the quality of life (QOL) of BMT recipients. QOL is typically viewed as a multidimensional construct, incorporating information regarding individuals' current physical symptoms and general health perceptions as well as information regarding physical, emotional, occupational and interpersonal functioning (Ware, 1984; Moinpour et al., 1989) . With long-term disease-free survival following BMT increasingly likely, knowledge of post-BMT QOL has become increasingly significant (Andrykowski, 1994) .
Research examining post-BMT QOL has appeared with increasing frequency in recent years (Andrykowski et al., 1990; Baker et al., 1991 Baker et al., , 1994 Wingard et al., 1991 Wingard et al., , 1994 Belec, 1992; Chao et al., 1992; Mumma et al., 1992; Vose et al., 1992; Schmidt et al., 1993; Syrjala et al., 1993) . This research has shown that while many adult BMT recipients exhibit few functional and psychosocial deficits and experience what could be considered a 'normal' QOL, other recipients experience functional and psychosocial 'late effects', including low self-esteem, occupational disability, sexual dysfunction, cognitive impairment and psychological distress. While some studies have linked poorer post-BMT QOL to older age at BMT, increased dose of total body irradiation (TBI) received in pre-BMT conditioning, presence of chronic GVHD, and lower level of education, results have not been consistent across investigations (Lesko, 1993; Andrykowski, 1994) . Other disease and treatment variables that might be linked with post-BMT QOL outcomes, such as diagnosis and disease status at BMT, extent of marrow graft match, or even type of BMT, have been largely unexamined in previous research. If one assumes that patients with more advanced disease have undergone more extensive cytotoxic treatment before BMT and allogeneic recipients of more 'mismatched' grafts (e.g. haploidentical grafts) are more likely to receive more extensive pre-BMT conditioning regimens and/or GVHD prophylaxis, then one might hypothesise that poorer QOL outcomes would be associated with more advanced disease at BMT, poorer marrow graft match and allogeneic BMT.
Three basic questions are addressed in the present study: I What is the QOL of adult BMT recipients? 2 How does the QOL of autologous recipients compare with that of allogeneic recipients? 3 What demographic, disease and treatment variables are associated with variance in post-BMT QOL? With regard to the last two questions, it is hypothesised that better post-BMT QOL will be associated with less education, younger recipients, the absence of chronic GVHD, autologous BMT, less advanced disease at BMT, less TBI during pre-BMT conditioning and histocompatible marrow grafts.
Eligibility criteria included: (1) > 18 years of age; (2) > 12 months post allogeneic or autologous BMT; (3) in disease remission; and (4) English-speaking. Eligible patients were sent a letter describing the study and two copies of a consent form. Following return of a signed consent, the name, address and telephone number of the BMT recipient were forwarded to project headquarters at the University of Ken- Table II ). Domains were chosen based upon previous studies of post-BMT QOL as well as discussion with BMT medical staff. Using their own selfdefined standard, respondents were asked to indicate whether their present status in each of these domains was 'not normal', 'almost normal', or 'normal'. The Perceived Health Questionnaire (PHQ) used a ten-step health ladder (Cantril, l%5) to obtain respondents' ratings of (1) their current physical health, (2) the health of a typical person their age, and (3) their health before their illns. The Perceived Quality of Life Questionnaire (PQOL) obtained these same three ratings with respect to QOL. The Symptom Experience Report (SER) asd the presence during the past week of 20 physical symptoms. If present, symptom severity was rated using a seven-point Likert scale. The PHQ, PQOL and SER have been used in our prior QOL research with BMT candidates (Andrykowski et al., 1993) and recipients (Andrykowski et al., 1990) .
Data preparation and analysis Several indices were computed using standard procedures: (1) SIP, scores for each of the five subscales used, (2) PAIS; subscale score for sexual relationships (PAIS-sex) and (3) POMS; total mood disturbane score (POMS-TMD) and subscale scores for depression (D), anger (A), tension (T), vigour (V), fatigue (F) and confusion (C). POMS-TMD scores were computed using the formula D + A + T + F + C+(32-V) (Andrykowski et al., 1990) .
Two other indices were computed. Scores for the five SIP subscales were summed and divided by 5 to create a total illness-related dysfunction score (SIP-total (Table II) indicated that, for each ROF item, autologous recipients reported better status than allogeneic recipients. Univariate ANOVA for each ROF item revealed significant differences between autologous and allogeneic recipients for 'workling outside the home' (F= 4.41, P<0.05) and 'personal appearance' (F= 16.86, P<0.001 Finally, our data support previous research suggesting that chronic GVHD is not associated with post-BMT QOL (Andrykowski et al., 1990) . Because of the wide use of GVHD prophylaxis, GVHD was generally mikL, thus limiting its potential impact on QOL. Chronic GVHD was associated only with poorer sexual relationship functioning in allogeneic recipients and was primarily due to the greater concern regarding personal appearance among those with chronic GVHD. New findings from the present study include observations that post-BMT QOL is associated to some degree with disease status at BMT, type of BMT and time since BMT. Poorer QOL was associated with more advanced disease at BMT. This was particularly apparent for indices of functional status (SIP-total, ROF-total) and for allogeneic recipients. Since this variable has not been examined in previous studies of post-BMT QOL, replication is warranted. However, this finding suggests that physical and functional recovery may be inversely associated with extent of pre-BMT cytotoxic treatment. Relative to autologous recipients, allogeneic recipients reported poorer QOL. Allogeneic recipients reported: (a) less 'normal' functioning on the ROF, (b) more physical symptoms, (c) poorer sexual relationship functioning and (d) more unemployment. While reasons for the poorer QOL of allogeneic recipients cannot be unambigously determined in the absence of a population-based (i.e. single disease) prospective study, our findings are helpful from both clinical and policy perspectives. To the degree that our sample is representative of the allogeneic and autologous BMT experience, our data suggest that, in general, autologous BMT is associated with fewer post-BMT QOL deficits. This information could be helpful in the process of obtaining informed consent as well as planning for delivery of clinical rehabilitation services. Finally, a consistent, positive relationship between time post BMT and QOL indices of functional status was obtained. In contrast to previous research (Wolcott et al., 1986; Andrykowski et al., 1989; Belec, 1992) our data suggest that functional status might improve across time following the first year post BMT. Prospective, longitudinal research will be necessary to establish more firmly the temporary trajectory of QOL outcomes. Establishment of the type and timing of specific QOL deficits is critical to the timing of rehabilitation efforts to promote post-BMT QOL.
In addition to identifying variables associated with post-BMT QOL, our study identified variables which were consistently not associated with post-BMT QOL. These included differences in underlying diagnosis, dose of TBI and, for allogeneic recipients, extent of marrow graft match and type of GVHD prophylaxis. Analyses of the relationships between QOL and disease diagnosis, extent of marrow graft match and GVHD prophylaxis are unique to this study and thus merit replication. However, our finding of a lack of association between TBI dose and QOL contrasts with previous research (Andrykowski et al., 1990) . This difference could be due to study differences (Andrykowski, 1990; Belec, 1992; Mumma et al., 1992) , difficulties with regard to reduced weakness, fatigue and the ability to engage in vigorous activities were pronounced. Clearly, more detailed study of fatigue in adult BMT recipients is warranted. Also consistent with previous research (Andrykowski et al., 1990; Wingard et al., 1991; Syrjala et al., 1993) , evidence for employment difficulties among BMT recipients was found. A third of our sample were unemployed or-retired at the time of participation and cited health difficulties as the cause of such. While loss of strength and stamina contributed to unemployment in some instances, other potential causes include discrimination directed at cancer survivors (Hoffman, 1991) , concerns over infection, hesitancy regarding relinquishment of the 'sick role' (Mechanic and Volkart, 1961) , or simply that the benefits of being unemployed exceed those of being employed. Unemployment among BMT survivors is a concern because of both the financial burdens borne by many BMT patients and their families as well as the link between unemployment and pyschosocial distress (Dew et al., 1991) . Sleep dffulties also emerged as a common complaint. 'Sleep problems' was the second most frequently reported symptom on the SER. Since research has not identified sleep dfficulties as a significant problem, further investigation of the aetiology and impact of sleep difficulties in BMT recipients is warranted, particularly in view of its potential contribution to fatigue in BMT patients.
Finally, reports of difficulties with sexual relationships and functioning were common, confirming previous investigations (Baruch et al., 1991; Chao et al., 1992; Mumma et al., 1992; Vose et al., 1992; Wingard et al., 1994) . Comparison of PAIS-sex scores in our sample with cancer patient norms (Derogatis and Lopez, 1983) indicated that 22 BMT recipients (12%) scored at least one standard deviation above the normative mean. Thus, about 12% of BMT recipients can be considered to be experiencing senous sexual relationship dysfunction relative to other cancer patients. Given that sexual dysfunction is more common in cancer patients relative to the general population (Andersen, 1985) , the number of BMT patients experiencng seious sexual relationship dysfucntion probably exceeds 12%. Such dysfunction is probably multifactorial in origin. Cytotoxic chemotherapy is known to affect gonadal function in both sexes (Sherins and Mulvihill, 1989 ) and can have a marked impact upon sexual response in females (Lesko, 1993) . Ovarian failure is a common sequela of cytotoxic chemotherapy, resulting in symptoms of vaginal dryness, dysparaeunia, decreased libido and vaginal epithelium atrophy (Sanders et al., 1988 (Sanders et al., , 1989 Cust et al., 1989; Schubert et al., 1990) . While risk for postchemotherapy ovarian failure increases with age, even younger women may exhibit transient symptoms of ovarian dysfunction for 2-6 years post BMT (Sanders et al., 1988 
Conclusion
Maximisation of post-BMT QOL requires rehabilitation services targeted for specific areas of difficulty in specific recipients at specific times during post-BMT recovery. Past research has done well in identifying areas where QOL might be compromised following BMT, but more in-depth studies of specific areas of difficulty, for example sexual functioning, underemployment, fatigue or sleep disturbance, would be useful. In contrast, less progress has been made in identifying specific BMT patients at risk for post-BMT difficulties, and still less progress has been made regarding identification of critical periods following BMT when particular difficulties might be manifest. Our data suggest that only a minority of variation in post-BMT QOL can be accounted for by demographic, disease and treatment variables. Understanding of variation in post-BMT QOL will require consideration of variables such as social support, coping style, psychiatric history or pre-BMT expectations, and longitudinal research will be needed to map the temporal trajectory of post-BMT QOL and suggest critical periods when QOL might be compromised.
